

# INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/617,569
Filing Date	July 11, 2003
First Named Inventor	ROBINSON, Robin A.
Art Unit	1648
Examiner Name	HILL, Myron G.
Attorney Docket Number	NOVV-003/00US 305047-2004

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	4552758	11/12/1985	Murphy et al.	
	2.	7556940	07/07/2009	Galarza et al.	
	3.	7763450	07/27/2010	Robinson et al.	
	4.	20060263804	11/23/2006	Robinson et al.	
	5.	20070184526	08/09/2007	Smith et al.	
	6.	20100129401	05/27/2010	Smith et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
	7.	WO 96/10633 A1	04/11/1996	Aviron et al.		
	8.	EP 0870508 A1	10/14/1998	Duphar International Research B.V.		

## NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Date Considered	T <sup>6</sup>

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

# INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/617,569
Filing Date	July 11, 2003
First Named Inventor	ROBINSON, Robin A.
Art Unit	1648
Examiner Name	HILL, Myron G.
Attorney Docket Number	NOVV-003/00US 305047-2004

## NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	9.	The Patent Office of the People's Republic of China, "The Decision of Final Rejection of the Application," 4 pages, from China Patent Appl. No. 200480026152.3 (issued May 20, 2010)	
	10.	Bender et al., "Characterization of the Surface Proteins of Influenza A (H5N1) Viruses Isolated from Humans in 1997-1998," Virology 254:115-123 (1999)	
	11.	Bright et al., "Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle," PLOS One, Public Library of Science 3:1501 (2008)	
	12.	Bucher et al., "Incorporation of Influenza Virus M-Protein into Liposomes," J. Virol. 36:586-590 (1980)	
	13.	Chambers et al., "A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome <sup>TM</sup> ) protects guinea pigs from lethal tuberculosis," Vaccine 22:1063-1071 (2004)	
	14.	Chen et al., "Avian flu: H5N1 virus outbreak in migratory waterfowl," Nature 436:191-192 (2005)	
	15.	Chen et al., "The Evolution of H5N1 Influenza Viruses in Ducks in Southern China," Proc. Natl. Acad. Sci. USA 101:10452-10457 (2004)	
	16.	Das et al., "Structural basis for suppression of a host antiviral response by influenza A virus," Proc. Natl. Acad. Sci. USA 105:13093-13098 (2008)	
	17.	DATABASE UniProt [Online] 1 October 2004 (2004-10-01), HONGB0 Z ET AL.: "Matrix protein 1" XP002526328 retrieved from <a href="http://WWW.UNIPROT.ORG/UNIPROT/Q6B3P4">HTTP://WWW.UNIPROT.ORG/UNIPROT/Q6B3P4</a> Database accession no. Q6B3P4	
	18.	DATABASE UniProt [Online] 11 July 2006 (2006-07-11), HOFFMANN E ET AL.: "Hemagglutinin" XP002526332 retrieved from <a href="http://WWW.UNIPROT.ORG/UNIPROT/Q195D4">HTTP://WWW.UNIPROT.ORG/UNIPROT/Q195D4</a> Database accession no. Q195D4	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (or by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and maintaining the required application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

# INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/617,569
Filing Date	July 11, 2003
First Named Inventor	ROBINSON, Robin A.
Art Unit	1648
Examiner Name	HILL, Myron G.
Attorney Docket Number	NOVV-003/00US 305047-2004

## NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>4</sup>
	19.	DATABASE UniProt [Online] 13 September 2005 (2005-09-13), CHEN H ET AL: "Neuramidase" XP002526329 retrieved from HTTP://WWW.UNIPROT.ORG/UNIPROT/Q4FB59 Database accession no. Q4FB59	
	20.	DATABASE UniProt [Online] 16 August 2004 (2004-08-16), LI KS ET AL.: "Hemagglutinin" XP002526330 retrieved from HTTP://WWW.UNIPROT.ORG/UNIPROT/Q6DQ47 Database accession no. Q6DQ47	
	21.	DATABASE UniProt 25 October 2004 (2004-10-25), LI KS ET AL: "Neuramidase" XP002526331 retrieved from HTTP://WWW.UNIPROT.ORG/UNIPROT/Q6DPH6 Database accession no. Q6DPH6	
	22.	Ebel, Search Report and Written Opinion, 9 pages, from Singapore Patent Appl. No. 200701731-2 (mailed February 25, 2010)	
	23.	Galarza et al., "Virus-Like Particle (VLP) Conferred Complete Protection Against a Lethal Influenza Virus Challenge," Viral Immunol. 18:244-251 (2005)	
	24.	Galarza et al., "Virus-Like Particle Vaccine Conferred Complete Protection Against a Lethal Influenza Virus Challenge," Viral Immunol. 18:365-372 (2005)	
	25.	Germann et al., "Mitigation Strategies for Pandemic Influenza in the United States," Proc. Natl. Acad. Sci. USA 103:5935-5940 (2006)	
	26.	Gregoridis et al., "Vaccine Entrapment in Liposomes," Methods 19:156-162 (1999)	
	27.	Heiduschat, "Supplementary European Search Report," 12 pages, from EP Appl. No. 06826264.1, European Patent Office, Munich, Germany (mailed May 28, 2009)	
	28.	Li et al., "Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia," Nature 430:209-213 (2004)	

Examiner Signature:		Date Considered:	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

The collection of this information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (or by the USPTO to process) an application. Collection is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including preparing, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

# INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/617,569
Filing Date	July 11, 2003
First Named Inventor	ROBINSON, Robin A.
Art Unit	1648
Examiner Name	HILL, Myron G.
Attorney Docket Number	NOVV-003/00US 305047-2004

## NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	29.	Li et al., "Recombinant Influenza A Virus Vaccines for the Pathogenic Human A/Hong Kong/97 (H5N1) Viruses," <i>J. Infect. Dis.</i> 179:1132-1138 (1999)	
	30.	Logrippo, "Investigations of the use of beta-propiolactone in virus inactivation," <i>Ann. N.Y. Acad. Sci.</i> 83:578-594 (1960)	
	31.	Matsuda, "Notice of Reasons for Rejection," 3 pages, Japan Patent Appl. No. 2006-518925, with 4 page translation (mailed March 17, 2010)	
	32.	NCBI Accession No. CY014173, "Influenza A virus (A/Indonesia/5/2005 (H5N1)) segment 7 sequence," 3 pages (available 8/30/06)	
	33.	Nerome et al., "Development of a new type of influenza subunit vaccine made by muramyl dipeptide-liposome: enhancement of humoral and cellular immune responses," <i>Vaccine</i> 8:503-509 (1990)	5
	34.	Neumann et al., "An Improved Reverse Genetics System for Influenza A Virus Generation and its Implications for Vaccine Production," <i>Proc. Natl. Acad. Sci. USA</i> 102:16825-16829 (2005)	
	35.	Palese, "Making Better Influenza Vaccines?" <i>Emerg. Infect. Dis.</i> 12:61-65 (2006)	
	36.	Park, Man-Seong, et al., "Engineered Viral Vaccine Constructs with Dual Specificity: Avian Influenza and Newcastle Disease," <i>Proc. Natl. Acad. Sci. USA</i> 103:8203-8208 (2006)	
	37.	Piedra et al., "Herd Immunity in Adults Against Influenza-Related Illnesses with use of the Trivalent-Live Attenuated Influenza Vaccine (CAIV-T) in Children," <i>Vaccine</i> 23:1540-1548 (2005)	
	38.	Pushko et al., "Influenza Virus-Like Particles Comprised of the HA, NA, and M1 proteins of H9N2 Influenza Virus Induce Protective Immune Responses in BALB/c Mice," <i>Vaccine</i> 23:5751-5759 (2005)	
	39.	Smith et al., U.S. application no. 12/558,844, filed September 14, 2009	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (or by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

# INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/617,569
Filing Date	July 11, 2003
First Named Inventor	ROBINSON, Robin A.
Art Unit	1648
Examiner Name	HILL, Myron G.
Attorney Docket Number	NOVV-003/00US 305047-2004

## NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	40.	Smith et al., U.S. application no. 12/832,657, filed July 8, 2010	
	41.	Treanor et al., "Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine," N. Engl. J. Med. 354:1343-1351 (2006)	
	42.	Welsh, "Examiner's first report on patent application no. 2004268510," 3 pages, from Australian Patent Appl. No. 2004268510 (dated February 5, 2010)	
	43.	Wiebke, "Communication pursuant to Article 94(3) EPC," 4 pages, from EP Appl. No. 04786052.3, European Patent Office, Munich, Germany (mailed March 19, 2010)	
	44.	Wiebke, "Communication pursuant to Article 94(3) EPC," 7 pages, from EP Appl. No. 04786052.3, European Patent Office, Munich, Germany (mailed September 15, 2008)	
	45.	Wiebke, "Supplementary European Search Report," 6 pages, from EP Appl. No. 04786052.3, European Patent Office, Munich, Germany (mailed March 26, 2008)	
	46.	Wood et al., "Preparation of Vaccines Against H5N1 Influenza," Vaccine, 20:S84-S87 (2002)	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.